Chemical Structure : DS-1001b
CAS No.: 1898207-64-1
Catalog No.: PC-38189Not For Human Use, Lab Use Only.
DS-1001b (DS1001b) is a potent, selective, BBB-permeable and orally bioavailable mutant IDH1 inhibitor with IC50 of 8.4/11 nM against IDH1 R132H/R132C mutants.
Packing | Price | Stock | Quantity |
---|---|---|---|
10 mg | $118 | In stock | |
25 mg | $198 | In stock | |
50 mg | $328 | In stock | |
100 mg | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
DS-1001b (DS1001b, Safusidenib) is a potent, selective, BBB-permeable and orally bioavailable mutant IDH1 inhibitor with IC50 of 8.4/11 nM against IDH1 R132H/R132C mutants.
DS-1001b strongly inhibited mutant IDH1, but not wild-type IDH1 or mutant IDH2 (IC50>10 uM).
DS-1001b impairs the proliferation of IDH1 mutant GBM cells and induces differentiation in a subcutaneous PDX model, but not the growth of IDH wild-type GBM.
DS-1001b permeates the BBB and inhibits tumor growth in an orthotopic PDX model.
M.Wt | 608.916 | |
Formula | C29H29Cl3FN3O4 | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
2-methylpropan-2-amine (E)-3-(1-(5-(2-fluoropropan-2-yl)-3-(2,4,6-trichlorophenyl)isoxazole-4-carbonyl)-3-methyl-1H-indol-4-yl)acrylate |
1. Yukino Machida, et al. Mol Cancer Ther. 2020 Feb;19(2):375-383.
2. Nakagawa M, et al. Oncogene. 2019 Oct;38(42):6835-6849.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright